PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma
Status:
Completed
Trial end date:
2020-09-30
Target enrollment:
Participant gender:
Summary
This is the first study to evaluate the safety and clinical activity of the combination of
oral pazopanib, intravenous or oral irinotecan, and oral temozolomide in pediatric and young
adult patients with relapsed or refractory sarcomas. This study will use a 3 + 3 design for
dose escalation (Part 1), followed by an expansion cohort (Part 2) at the recommended phase 2
dose level.
Phase:
Phase 1
Details
Lead Sponsor:
University of California, San Francisco
Collaborators:
Alex's Lemonade Stand Foundation Children's Hospital & Research Center Oakland Dana-Farber Cancer Institute UCSF Benioff Children's Hospital Oakland